Home » Key Drug Discovery Articles » Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer.

Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer.

Polański R, Hodgkinson CL, Fusi A, Nonaka D, Priest L, Kelly P, Trapani F, Bishop PW, White A, Critchlow SE, Smith PD,Blackhall F, Dive C, Morrow CJ.

Clin Cancer Res. 2014 Feb 15;20(4):926-37.

Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute; Faculty of Life Sciences and Medical and Human Sciences, Manchester Academic Health Sciences Centre, University of Manchester;Christie National Health Service Foundation Trus; University Hospital of South Manchester National Health Service Foundation Trust, Manchester; and Oncology iMED, AstraZeneca, Macclesfield, United Kingdom.
The monocarboxylate transporter 1 (MCT1) inhibitor, AZD3965, is undergoing phase I evaluation in the United Kingdom. AZD3965 is proposed, via lactate transport modulation, to kill tumor cells reliant on glycolysis. We investigated the therapeutic potential of AZD3965 in small cell lung cancer (SCLC) seeking rationale for clinical testing in this disease and putative predictive biomarkers for trial use.
AZD3965 sensitivity was determined for seven SCLC cell lines, in normoxia and hypoxia, and for a tumor xenograft model. Proof of mechanism was sought via changes in intracellular/tumor lactate. Expression of MCT1 and related transporter MCT4 was assessed by Western blot analysis. Drug resistance was investigated via MCT4 siRNAi and overexpression. The expression and clinical significance of MCT1 and MCT4 were explored in a tissue microarray (TMA) from 78 patients with SCLC.
AZD3965 sensitivity varied in vitro and was highest in hypoxia. Resistance in hypoxia was associated with increased MCT4 expression. In vivo, AZD3965 reduced tumor growth and increased intratumor lactate. In the TMA, high MCT1 expression was associated with worse prognosis (P = 0.014). MCT1 and hypoxia marker CA IX expression in the absence of MCT4 was observed in 21% of SCLC tumors.
This study provides a rationale to test AZD3965 in patients with SCLC. Our results suggest that patients with tumors expressing MCT1 and lacking in MCT4 are most likely to respond.
©2013 AACR.

Go To PubMed

monocarboxylate transporter 1